Diffuse Large B Cell Lymphoma: Immunohistochemical Classification According to Hans Algorithm and Association With...

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
• DLBCL is classified into two main molecular subtypes: germinal center B-cell (GCB) and non-germinal center B-cell (non-GCB), identified via immunohistochemistry.
• These subtypes exhibit distinct biological characteristics.

Purpose of the Study:

• To investigate the impact of DLBCL immunohistochemical subtypes (GCB vs. non-GCB) on patient demographics and clinicopathological features.
• To analyze the correlation between DLBCL subtypes and response to chemotherapy.
• To evaluate the influence of DLBCL subtypes on survival outcomes.

Main Methods:

• A retrospective study of 106 DLBCL cases from January 2010 to September 2022 in Fez, Morocco.
• DLBCL subtypes were determined using the Hans algorithm with immunohistochemistry for CD10, BCL6, and MUM1.
• Statistical analysis included independent t-tests and ANOVAs using SPSS 26.0, with P < .05 considered significant.

Main Results:

• The non-GCB subtype comprised 71% of cases, while the GCB subtype accounted for 29%.
• Significant correlations were observed between DLBCL immunosubtypes, treatment response, and survival (P < .05).
• The GCB subtype demonstrated significantly improved response rates and survival. Ki 67 expression was associated with survival on univariate and multivariate analyses.

Conclusions:

• The non-GCB subtype of DLBCL is associated with poorer treatment response and survival in the Moroccan population compared to the GCB subtype.
• High Ki 67 expression further exacerbates the inferior survival outcomes in the non-GCB subtype.
• Immunohistochemical subtyping of DLBCL is crucial for predicting treatment response and survival.